NEP outperformed eight other peptide providers in the peptide comparison study conducted by Covance Research Products - a subsidiary of the giant contract research organisation (CRO).
The study evaluated the performance of peptide providers across key product and service quality criteria.
Each company had to make the same peptide sequence for the production of custom polyclonal antibodies, which were then analysed by Enzyme-Linked ImmunoSorbent Assay (ELISA) on the associated serum - which detects the presence of antibody.
The peptide NEP produced for the test produced an antibody with an ELISA mean antibody titer twice that of the closest competitor.
In addition, the study ranked NEP first in customer service among the nine companies.
"The study provides concrete data that distinguishes NEP in the industry," said Dave Robinson, NEP's CEO.
"Since drug discovery project success is unquestionably linked to the quality of the active ingredient, NEP welcomed this opportunity to compare quality and service with others in the market.
The results speak for themselves."
With drug makers and contract research organisations (CROs) increasingly focusing on biologics, the growing demand for higher quality peptides and large peptide libraries for screening applications is driving strong annual growth.
And to stay ahead of the game, peptide providers must assure higher quality-control standards while driving down costs, in order to maintain a competitive advantage.
NEP, headquartered in Massachusetts, designs and manufactures peptide and antibody products for drug discovery companies and specialises in custom peptide synthesis and polyclonal antibody production.